Cargando…
Understanding patient and physician responses to various cost-sharing programs for prescription drugs in South Korea: A multilevel analysis
INTRODUCTION: Patient and/or physician responses are a pivotal issue in designing rational cost-sharing programs under health insurance systems. OBJECTIVES: This study aims to understand patient and/or physician responses to cost-sharing programs designed for prescription drugs in South Korea. METHO...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471326/ https://www.ncbi.nlm.nih.gov/pubmed/36117604 http://dx.doi.org/10.3389/fpubh.2022.924992 |
Sumario: | INTRODUCTION: Patient and/or physician responses are a pivotal issue in designing rational cost-sharing programs under health insurance systems. OBJECTIVES: This study aims to understand patient and/or physician responses to cost-sharing programs designed for prescription drugs in South Korea. METHODS: As a framework, we took advantage of a tiered cost-sharing program, including from copayment to coinsurance (threshold 1) and reduced coinsurance (threshold 2). Given the hierarchical structure of prescriptions nested within patients, we utilized a multilevel analysis to assess effects of various cost-sharing programs on patient and/or physician responses using National Health Insurance claims data from 2018. RESULTS: We found that a tiered cost-sharing program was effective in changing the behaviors of patients and/or physicians. Threshold 1 was found to be more effective than threshold 2 in changing their behaviors. At the prescription level, sensitivity to cost-sharing programs was associated with prescribed days of treatment and locations of prescription. In a similar vein, sensitivity to cost-sharing programs was associated with gender and age group of patients. CONCLUSION: A simplified cost-sharing program with extended intervals should be considered to rationalize cost-sharing programs. Specifically, a cost-sharing program designed for long-term prescriptions for chronic diseases together with an emphasis on cost transparency is required to better guide price-conscious decisions by patients and/or physicians. |
---|